NUVL – nuvalent, inc. - class a (US:NASDAQ)
Stock Stats
News
Jefferies starts Nuvalent at buy, cites lung cancer drug candidates [Seeking Alpha]
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $97.00 price target on the stock.
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at Leerink Partnrs from a "market perform" rating to an "outperform" rating.
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $110.00 price target on the stock, up previously from $69.00.
Form 4 Nuvalent, Inc. For: May 02 Filed by: Miller Deborah Ann
Form 4 Nuvalent, Inc. For: Apr 29 Filed by: Shair Matthew
Form ARS Nuvalent, Inc. For: Dec 31
Form DEFA14A Nuvalent, Inc.
Form DEF 14A Nuvalent, Inc. For: Jun 12
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.